SOPHiA GENETICS SA
SOPHiA GENETICS SA Ordinary Shares is the equity of SOPHiA GENETICS, a healthcare technology company focused on data-driven medicine and life sciences research. The company develops cloud-native software that analyzes complex genomic and multimodal healthcare data, helping hospitals, laboratories, and biopharmaceutical organizations generate actionable insights across cancer, rare disorders, and other diagnostic areas. Its core platform, SOPHiA DDM, supports the interpretation of data from multiple testing modalities, including genomics, radiomics, clinical information, biological data, and digital pathology. SOPHiA GENETICS serves a global network of healthcare and research institutions that use its software to streamline analysis and support more coordinated diagnostic workflows. Headquartered in Rolle, Switzerland, SOPHiA GENETICS operates at the intersection of healthcare, artificial intelligence, and precision medicine, making it an important provider of digital tools for modern clinical and research environments.
$6.73
-$0.56 (-7.68%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-91.76% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 18.6% YoY with margins expanding 10.4pp.
ROIC dropped from -35.47% to -47.33%, capital efficiency is deteriorating. Negative free cash flow of -$45M. The business is consuming cash, not generating it.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$86M
▲ +18.6% YoY
Net Income (TTM)
-$81M
▼ -26.4% YoY
Op. Margin
-85.55%
▲ +10.4pp YoY
ROIC
-47.33%
▼ -11.9pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$50M
▲ +12.7% YoY
Op. Cash Flow (TTM)
-$40M
▲ +17.6% YoY
Net Debt
-$7M
Net Cash Position
Cash & Equiv.
$70M
3Y CAGR: +17.6%
Continue Research
Is SOPHiA GENETICS SA (SOPH) overvalued?
SOPHiA GENETICS SA (SOPH)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, SOPHiA GENETICS SA scores 40/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from company filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
Is SOPHiA GENETICS SA a high-quality business?+
SOPHiA GENETICS SA scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a mixed business on these measures. Recent fundamentals include a -85.5% operating margin and a -47.3% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from company filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is SOPHiA GENETICS SA a good stock to buy right now?+
That depends on valuation and quality together, not either alone. you should weigh SOPH's valuation and scores 40/100 on quality (mixed). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from company filings, not investment advice.
Related stocks: Health Information Services
Spot a number that looks wrong?
Data sourced from company filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.